Synthetic Biology Company Intrexon Raises $150M in Series F Preferred Investment Round | GenomeWeb

NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon said late Wednesday that it has closed a Series F preferred investment round that raised $150 million.

Proceeds from the financing round will be used for working capital to establish additional channel collaborations in the firm's core sectors, including healthcare, food, energy, and environment, it said, adding that funding will also be used for further development of its technology platforms and expansion of its sales and marketing and R&D efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.